jueves, 8 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 11, 2026

TPG Calls 2025 a “Breakout Year” at BofA Conference, Targets Another $50B+ Fundraising Year

View original at finance.yahoo.com
TPG Calls 2025 a “Breakout Year” at BofA Conference, Targets Another $50B+ Fundraising Year TPG logo Key Points TPG called 2025 a “breakout year,” having raised about $51 billion (vs…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • TPG has averaged roughly $25 billion per year in realizations over the past five years

    80% confidence
  • 2025 was a 'breakout year' for TPG

    80% confidence
  • By end of January 2025, TPOP had raised about $1.5 billion with a relatively limited initial distribution footprint

    80% confidence
  • Credit fundraising exceeded $20 billion in 2025

    80% confidence
  • The Jackson investment management agreement begins at $12 billion, can scale over time, and has potential to expand to $20 billion

    80% confidence
  • TPG's real estate track record is very, very strong, and early LP dialogue has been supportive

    80% confidence
  • TPG expects another robust fundraising year in 2026, with fundraising again in excess of $50 billion

    80% confidence
  • TPG plans to be in market with about 35 products in 2026 versus about 25 products in 2025

    80% confidence
  • TPG expects to be in market with at least four different real estate funds during 2026

    80% confidence
  • TPG raised approximately $51 billion of capital in 2025, up from $30 billion the prior year, about a 70% increase

    80% confidence
  • LPs frequently cite TPG as a consistent generator of DPI

    80% confidence
  • About 11% of total AUM is in software, with approximately 2% in credit and about 18% of private equity AUM in software companies

    80% confidence
  • At IPO, last-twelve-month FRE was a little more than $300 million

    80% confidence
  • Twin Brook's entry leverage is typically in the 3.5x to 4x range versus higher leverage levels in larger-company direct lending

    80% confidence
  • At the time of IPO, roughly 80% of AUM was in private equity; today, private equity represents about 50% of AUM

    80% confidence
  • TPG has expanded its FRE margin by roughly 800 basis points since the IPO, from around 37% to 45% in 2025, with target of about 47% in 2026

    80% confidence
  • TPG deployed a little more than $50 billion during 2025

    80% confidence
  • TPG was a significant net seller in 2021, selling every software company in a mature private equity fund by the end of 2021

    80% confidence
  • TPG is investing $500 million in Jackson equity to help capitalize a new vehicle

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com